Adoptive cell transfer (ACT) involving either genetically modified or unmanipulated cells is
one of the leading forms of cancer immunotherapy currently in development. While ACT has …

The treatment of cancer with adoptive cell therapy is largely limited to platforms based on
circulating, patient-derived, engineered autologous αβ T cells. Although successful in some …

The treatment of haematologic malignancies with adoptive cell therapy is largely limited to
platforms based on patient-derived, autologous αβ T cells. Although successful, this …

The treatment of haematological malignancies with adoptive cell therapy such as leukaemia
is limited to conventional ab T cells transduced at great cost with chimeric antigen receptors …

The γδT cell subset of peripheral lymphocytes exhibits potent cancer antigen recognition
independent of classical peptide MHC complexes, making it an attractive candidate for …

Vδ2Vγ9 T cells are the dominant γδ T-cell subset in human peripheral blood. Vδ2 T cells
recognize pyrophosphate molecules derived from microbes or tumor cells; hence, they play …

Gamma delta T (γδT) cells are innate-like lymphocytes with strong, MHC-unrestricted
cytotoxicity against cancer cells and show a promising prospect in adoptive cellular …

Chimeric antigen receptor (CAR) modification of αβ T cells has revolutionized the field of
oncology, driving the focus of attention to the immune system to target and fight …

The human Vγ9Vδ2 T cell is a unique cell type that holds great potential in immunotherapy
of cancer. In particular, the therapeutic potential of this cell type in adoptive cell therapy …

Cancer immunotherapy has shown great advances during recent years, but it has yet to
reach its full potential in all cancer types. Adoptive cell therapy (ACT) is now an approved …